Econazole: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: March 6, 2026🚩 Report this page

Econazole

Active ingredient · 2 therapeutic classes

GB MHRA

Drug class: Imidazole Derivatives
Availability: See label
Markets covered: 1
Products on record: 4

G01AFImidazole Derivatives D01ACImidazole and Triazole Derivatives

Overview

Econazole is an active pharmaceutical ingredient in the Imidazole Derivatives group (G01AF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	4	March 6, 2026

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised December 9, 2024[1]

For the treatment of cutaneous candidiasis, dermatophytosis and pityriasis versicolor.

How to take

GBOfficial regulatory label

Drug interactions

Known interactions involving Econazole. Select one for details. This list is informational and not a complete interaction checker.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL505670007 · revised December 9, 2024

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised December 9, 2024[1]

The safety of econazole nitrate cream (1%) and econazole nitrate emulsion (1%) was evaluated in 470 subjects who participated in 12 clinical trials and received at least one administration of either formulation. 1%). Including the above-mentioned adverse reactions, the following table displays adverse reactions that have been reported with the use of PEVARYL Dermatological Formulations from either clinical trial or post-marketing experiences.
The displayed frequency categories use the following convention:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available clinical trial data). In the PEVARYL Dermatological Formulations adverse reaction table below, all adverse reactions with a known incidence (common or uncommon) are from clinical trial data and all adverse reactions with an unknown incidence are from post-marketing data.
Table 1:
Adverse Reactions Adverse Reactions Frequency Category System Organ Class Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Not Known Immune System Disorder Hypersensitivity Skin and Subcutaneous Tissue Disorders Pruritus Skin burning sensation Erythema Angioedema Contact dermatitis Rash Urticaria Blister Skin exfoliation General Disorders and Administration Site Conditions Pain Discomfort Swelling Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised December 9, 2024[1]

For external use only. Care should be taken not to get Pevaryl Topical Cream in the eyes or mouth. If the product is accidently applied to the eyes the patient should wash with clean water or saline and seek medical attention if symptoms persist.
If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued. Care should be taken in the presence of eczematous dermatitis. Excipients This medicine contains 30 mg benzoic acid in each tube of 15 g which is equivalent to 2 mg/g cream.
This medicine contains 60 mg benzoic acid in each tube of 30 g which is equivalent to 2 mg/g cream. Benzoic acid may cause local irritation. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).
g. contact dermatitis) or irritation to the eyes and mucous membranes.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations